Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL9421490 | 0.88 | CA2 (0.44) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL4965571 | 0.88 | CA2 (0.47) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL221388 | 0.88 | — | — | |
| SCHEMBL23556 | 0.88 | — | — | |
| SCHEMBL220145 | 0.88 | — | — | |
| SCHEMBL9423852 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL9423640 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL21775798 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL9423643 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL19995171 | 0.83 | CA2 (0.40) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9820927-B2 | Aqueous oil in water micro-emulsions, and product | GIVAUDAN SA (CH) | 2017-11-21 | — | — | US | claimed |
| CN-106418487-A | Enteral nutrition emulsion containing batyl alcohol and preparation method thereof | 安徽华明制药有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-20140371128-A1 | Composition | GIVAUDAN SA (CH) | 2014-12-18 | — | — | US | claimed |
| EP-3515899-A1 | SOLKETAL-ETHERS, PRODUCTION METHOD AND USES THEREOF | Cepsa S.A.U. (ES) | 2019-07-31 | — | — | EP | disclosed |
| EP-3515899-A1 | SOLKETAL-ETHERS, PRODUCTION METHOD AND USES THEREOF | Cepsa S.A.U. (ES) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018055065-A1 | SOLKETAL-ETHERS, PRODUCTION METHOD AND USES THEREOF | CEPSA S.A.U. (ES) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018055065-A1 | SOLKETAL-ETHERS, PRODUCTION METHOD AND USES THEREOF | CEPSA S.A.U. (ES) | 2018-03-29 | — | — | WO | disclosed |
| CN-107412775-A | Method for treating neurological disorders with extracts of Nerium species or Thevetia species | 菲尼克斯生物技术公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-103429251-B | Method for treating neurological disorders with extracts of Nerium species or Thevetia species | 菲尼克斯生物技术公司 | 2017-09-15 | — | — | CN | disclosed |
| CN-106418487-A | Enteral nutrition emulsion containing batyl alcohol and preparation method thereof | 安徽华明制药有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2510788-B1 | Glyceryl ether compounds and their use | SEGETIS INC (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-1954139-A2 | GLYCERYL ETHER COMPOUNDS AND THEIR USE | Aromagen Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007062112-A2 | GLYCERYL ETHER COMPOUNDS AND THEIR USE | AROMAGEN CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-0786459-B1 | Process for the preparation of a hetero-bicyclic alcohol enantiomer | DUPHAR INT RES (NL) | 2002-08-28 | — | — | EP | disclosed |
| US-5948909-A | BLOCKING; CYCLIZATION | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1999-09-07 | — | — | US | disclosed |
| EP-0786459-A1 | Process for the preparation of a hetero-bicyclic alcohol enantiomer | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1997-07-30 | — | — | EP | disclosed |
| US-5110582-A | Storage stability | BASF AKTIENGESELLSCHAFT (DE) | 1992-05-05 | — | — | US | disclosed |
| US-4831109-A | Copolymerizable UV stabilizers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-05-16 | — | — | US | disclosed |
| US-4691059-A | Copolymerizable UV stabilizers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0213925-A2 | Copolymerizable UV stabilizers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371128-A1 | Composition | CUTA, C5, DEGS1 | CA2 3334/4885ALDH1A1 888/4885NPSR1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.